Table 1 HPV prevalence, fraction attributable to genotypes targeted by the 4-valent and nonavalent vaccines and potential absolute and relative benefit of the 9-valent vaccine compared to the 4-valent for each type of lesion
Lesion [sources] | HPV prevalence | HPV 6/11/16/18 attributable fraction among HPV+ cases | HPV 6/11/16/18/31/33/45/52/58 attributable fraction among HPV+ cases | HPV 31/33/45/52/58 absolute (relative) attributable fraction among HPV+ cases |
|---|---|---|---|---|
Genital warts [2] | 100% | 90% | 90% | 0% (0%) |
CIN 2/3 [2] | 100% | 45.5% | 82.3% | 36.8% (80.9%) |
VIN2/3 [8] | 86.9% | 80.9% | 93.9% | 13.0% (16.1%) |
VaIN 2/3 [9] | 98.0% | 65.7% | 79.0% | 13.3% (20.2%) |
AIN 2/3 [22] | 95.7% | 80.5% | 87.8% | 7.3% (9.1%) |
PIN 2/3 [10] | 89.1% | 81.0% | 91.9% | 10.9% (13.4%) |
Cervical cancer [21] | 100% | 72.4%(a) | 88.3%(a) | 15.9% (21.9%)(a) |
Vulvar cancer [8] | 18.3% (b) | 78.0% | 91.6% | 13.6% (17.4%) |
Vaginal cancer [9] | 71.0% | 64.0%(a) | 84.2%(a) | 20.2% (31.6%)(a) |
Anal cancer [22] | 87.6% | 84.3%(a) | 92.3%(a) | 8.0% (9.5%)(a) |
Penile cancer [10] | 32.2% | 70.2%(a) | 79.4%(a) | 9.2% (13.1%)(a) |
Oral cavity [23] | 7.4% | 72.0%(a) | 80.6%(a) | 8.6% (11.9%)(a) |
Nasopharynx [23] | 7,9% | 75.0%(a) | 87.5%(a) | 12.5% (16.7%)(a) |
Oropharynx cancer [23] | 24.9% | 85.2%(a) | 89.7%(a) | 4.5% (5.3%)(a) |
Hypopharynx cancer [23] | 3.9% | 80.0%(a) | 100%(a) | 20.0% (25.0%)(a) |
Pharynx cancer [23] | 21.4% | 66.7%(a) | 66.7%(a) | 0% (0%)(a) |
Larynx cancer [23] | 5.7% | 57.6%(a) | 74.6%(a) | 17.0% (29.5%)(a) |